MEND Micrus Endovascular (MM)

The Law Office of Joseph Klein is investigating the Board of Directors of Micrus Endovascular Corporation (“Micrus” or the “Company”) (NasdaqGM: MEND) for possible breaches of fiduciary duty and other violations of state law in connection with their attempt to sell the Company to Johnson & Johnson. ("J&J") (NYSE: JNJ). Under the terms of the transaction, Micrus shareholders will receive $23.40 in cash for each Micrus share of common stock they own for a total transaction value of approximately $480 million.

For the year ending March 31, 2010, Micrus reported total revenue of $91.090 million and net income of $11.530 million as compared to total revenue and a net loss of $78.196 million and $11.054 million, respectively, for the prior year. The investigation concerns whether the Micrus Board of Directors breached their fiduciary duties to Micrus stockholders by failing to adequately shop the Company before entering into this transaction and whether J&J is underpaying for Micrus shares, thus unlawfully harming Micrus stockholders. In particular, the offer price is only a small premium over the $22.24 price the Company's shares traded at as recently as February 19, 2010 and at least one analyst set a price target for Micrus stock at $25.00 per share.

If you own common stock in Micrus and wish to obtain additional information about this investigation and what is being done to advance the shareholders’ interests, please contact Joseph Klein, Esq. directly, via email at jk@jkleinlawfirm.com, by telephone at 718-947-0005, Toll Free: 877-STOK-180, or http://www.jkleinlawfirm.com/micrus-endovascular-mend.html. All consultations are confidential and free of charge.

To share your views on the proposed merger transaction and to see how other shareholders plan on voting, go to http://buyoutorsellout.com/web/mergers/micrus-endovascular.html.

Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation.

Micrus Endovascular (MM) (NASDAQ:MEND)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024

Micrus Endovascular (MM) (NASDAQ:MEND)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024